What is the treatment for Phencyclidine (PCP) intoxication?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: February 24, 2025 • View editorial policy

From the Research

The treatment for Phencyclidine (PCP) intoxication is primarily supportive, focusing on managing symptoms and preventing complications, as there is no specific antidote available. However, the provided evidence does not directly address Phencyclidine (PCP) intoxication but rather Pneumocystis pneumonia (PCP), which is a different condition.

Given the context of the question seems to be confused with Pneumocystis pneumonia (PCP), let's address the treatment for Pneumocystis pneumonia (PCP) based on the provided evidence:

Treatment Overview

  • The first-line treatment for Pneumocystis pneumonia (PCP) is trimethoprim-sulfamethoxazole (TMP-SMX), also known as co-trimoxazole 1.
  • For moderate to severe PCP, the recommended dose is often considered to be 15-20 mg/kg/day of the trimethoprim component, divided into 3 or 4 doses, given intravenously or orally for 21 days 2, 3.
  • For patients who cannot tolerate TMP-SMX, alternative treatments include intravenous pentamidine (4 mg/kg once daily), clindamycin plus primaquine, or atovaquone 1.
  • The duration of treatment with these alternatives is also typically 21 days.

Adjunctive Therapy

  • Adjunctive corticosteroids are recommended for moderate to severe PCP, defined as PaO2 <70 mmHg on room air or an alveolar-arterial oxygen gradient >35 mmHg 1.
  • Prednisone is typically given at 40 mg twice daily for 5 days, then 40 mg once daily for 5 days, followed by 20 mg daily for the remainder of the treatment course.

Secondary Prophylaxis

  • After successful treatment, patients with HIV should receive secondary prophylaxis with TMP-SMX (one double-strength tablet daily or three times weekly) until their CD4 count is consistently above 200 cells/μL for at least 3 months on antiretroviral therapy 1.

Considerations

  • The efficacy of TMP-SMX is due to its ability to inhibit folate synthesis in Pneumocystis jirovecii, the causative organism of PCP.
  • Corticosteroids help reduce the inflammatory response in the lungs, potentially preventing respiratory failure in severe cases.
  • Recent studies suggest that lower doses of TMP-SMX may be effective and reduce adverse effects 4, 3, but the optimal dosing strategy should be based on the most recent and highest quality evidence available.

Given the confusion in the question and the evidence provided, it's crucial to clarify that Phencyclidine (PCP) intoxication and Pneumocystis pneumonia (PCP) are two distinct conditions requiring different approaches to management. For Phencyclidine intoxication, treatment is supportive and focused on symptom management, whereas for Pneumocystis pneumonia, specific antimicrobial therapies like TMP-SMX are indicated.

Related Questions

What is the recommended treatment for Pneumocystis jirovecii pneumonia (PCP)?
What is the treatment for Pneumocystis jirovecii pneumonia (PCP pneumonia)?
What is the diagnosis and treatment for Phencyclidine (PCP) intoxication?
What is the recommended dose of Bactrim (Trimethoprim/Sulfamethoxazole) for Pneumocystis jirovecii pneumonia (PCP) prophylaxis?
What is the clinical summary of a patient with Acute Respiratory Distress Syndrome (ARDS) with a partial pressure of arterial oxygen to fraction of inspired oxygen (paO2/FiO2) ratio of 130 mmHg, indicating moderate severity, and diagnosed with Human Immunodeficiency Virus (HIV), with possible Pneumocystis jirovecii pneumonia or nosocomial pneumonia associated with mechanical ventilation due to Pseudomonas aeruginosa?
What is the pretest probability of a positive MRI (Magnetic Resonance Imaging) of the prostate if the Prostate-Specific Antigen (PSA) level is elevated and the Exo (External Beam Radiation Therapy) is not applicable, but rather the patient has a PSA level of 4 and an external factor of 19, which is likely referring to the patient's age or another clinical factor?
What are the implications of sclerotic foci in the lumbar spine?
What is the pretest probability of a positive Magnetic Resonance Imaging (MRI) of the prostate if the Prostate-Specific Antigen (PSA) level is elevated and the Exo (External) IntelliScore is 19?
What is the 10-year survival rate for high-grade prostate cancer?
Do vancomycin and piperacillin-tazobactam (pip-tazo) cover Escherichia coli (E. coli) urinary tract infections (UTI)?
What is the next step in evaluating a patient with elevated Thyroid-Stimulating Hormone (TSH) of 8.2, presenting with peripheral neuropathy, but without specific symptoms of hypothyroidism?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.